Company intelligence / Profile preview

A-Alpha Bio

Seattle, Washington, United Statesaalphabio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

A-Alpha Bio is developing platforms for measuring and predicting protein-protein interactions to accelerate therapeutic discovery. No specific clinical trial results were mentioned in the search results.

Therapeutic areas: OncologyNeurologyInfectious Diseases
Modalities: Protein therapeuticsMolecular gluesAntibodies
Industry: Biotech

Drug pipeline

1 asset

alpha

Preclinical

Partnerships

Department of Defense (DOD)Lawrence Livermore National Laboratory (LLNL)Lumen Bioscience"industry-leading pharmaceutical companies"

Beyond the preview

Go deeper on A-Alpha Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on A-Alpha Bio.

Explore the full profile